Library
Peptide index
Each profile covers what the compound is, what the research literature actually says, reconstitution math, storage timelines, and safety notes.
A small molecule researched for blocking NNMT enzyme to boost NAD+ levels and fat metabolism.
A research peptide that inhibits connective tissue growth factor (CCN2/CTGF), a key mediator of tissue fibrosis. Targets the fundamental fibrotic pathway involved in organ aging and disease.
A synthetic copper tripeptide analogue of GHK-Cu, researched for collagen synthesis and skin regeneration.
Dual amylin/GLP-1 receptor agonist from Novo Nordisk. Single molecule.
A modified hGH fragment researched for targeted fat breakdown without altering blood sugar or IGF-1.
A peptide ligand for the APJ receptor (APLNR) with potent cardiovascular, metabolic, and anti-aging effects. Apelin levels decline with aging and are reduced in cardiovascular disease.
An 11-amino acid peptide derived from erythropoietin (EPO) that activates the innate repair receptor (IRR) without stimulating erythropoiesis. Provides neuroprotection, anti-inflammatory, and tissue repair effects.
A topical hexapeptide that modulates the SNAP-25 protein complex to reduce expression lines. Functions as a topical alternative to botulinum toxin with a milder, non-paralytic mechanism.
A synthetic pentadecapeptide derived from a protein found in gastric juice. Studied for tissue repair, tendon/ligament healing, and gut protection in preclinical models.
BPC-157 Arginate is the arginine salt form of Body Protection Compound 157, a synthetic pentadecapeptide derived from a partial sequence of human gastric juice protein. This formulation pairs the BPC-157 peptide with arginine as a counter-ion, which proponents claim provides improved stability and enhanced oral bioavailability compared to the standard acetate salt form. The underlying peptide consists of 15 amino acids and has demonstrated cytoprotective, anti-inflammatory, and tissue-healing properties across numerous preclinical studies. It promotes angiogenesis, modulates nitric oxide pathways, and upregulates growth factor expression. The arginate form is marketed as offering better gastric survival and systemic absorption when taken orally, though direct head-to-head comparative data remains limited.
A long-acting amylin analog researched for satiety promotion and enhanced weight loss, particularly alongside semaglutide.
Brain-injury-homing tetrapeptide targeting chondroitin sulfate proteoglycans at injury sites.
A naturally occurring dipeptide (beta-alanine + histidine) with potent anti-glycation, antioxidant, and pH-buffering properties. Acts as an AGE inhibitor, preventing cross-linking of proteins that accelerates tissue aging.
A porcine-derived neuropeptide complex researched for neuroprotection, cognitive recovery, and stroke rehabilitation.
A modified GHRH analog with a short half-life. Commonly paired with a GHRP in research protocols to study pulsatile GH release.
A long-acting GHRH analogue research describes as sustaining elevated GH levels for up to eight days per dose.
Cortagen is a short synthetic bioregulator peptide developed by Professor Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology. It is designed to target the adrenal cortex, supporting the regulation of cortisol production and adrenal gland function. Bioregulator peptides are based on the concept that short peptide sequences derived from or mimicking endogenous tissue-specific peptides can restore gene expression patterns in aging or damaged tissues. Cortagen is proposed to normalise adrenal cortex function by interacting with DNA and modulating transcription of genes involved in steroidogenesis. While the bioregulator concept has theoretical appeal, the evidence base consists primarily of preclinical studies and observational reports from Russian clinical practice.
Degarelix is a synthetic decapeptide that functions as a gonadotropin-releasing hormone (GnRH) receptor antagonist. Marketed as Firmagon, it is used in the treatment of advanced hormone-dependent prostate cancer. Unlike GnRH agonists such as leuprolide, degarelix does not cause an initial surge in testosterone (the testosterone flare), making it particularly suitable for patients where rapid testosterone suppression is clinically necessary. It achieves castrate-level testosterone within three days of the initial dose, providing immediate therapeutic benefit. Degarelix works by competitively blocking GnRH receptors in the anterior pituitary, directly suppressing LH and FSH secretion without initial receptor stimulation.
A small peptide that mimics BDNF, with research noting potent neurogenesis and synapse formation in animal models.
A naturally occurring neuropeptide researched for its role in promoting delta wave sleep and circadian regulation.
Biased GLP-1 receptor agonist. Selectively activates cAMP over beta-arrestin reducing GI side effects.
Investigational long-acting amylin receptor agonist (Eli Lilly, code LY3841136) studied for appetite regulation and weight reduction. Early-stage clinical development.
A tetrapeptide researched for telomerase activation and potential influence on cellular ageing and circadian rhythms.
A synthetic tetrapeptide investigated in Russian gerontology literature for telomerase and pineal gland activity. Human data is limited and mostly small cohorts.
A GLP-1 receptor agonist derived from Gila monster peptide, researched for glycaemic control and weight reduction.
A glycoprotein that binds and neutralises myostatin, the protein that naturally limits muscle growth.
Experimental peptide researched for selectively triggering apoptosis in senescent, non-dividing cells.
A naturally occurring copper-binding peptide research associates with collagen synthesis and tissue remodelling.
A second-generation GHS-R agonist that research associates with significant pulsatile growth hormone release.
A first-generation GH secretagogue that stimulates GH release and strongly activates ghrelin-related appetite pathways.
Research describes glutathione as the body's primary endogenous antioxidant, studied for oxidative stress reduction and skin brightening.
Synthetic GnRH that research shows stimulates pituitary release of LH and FSH, supporting reproductive hormone regulation.
A 16-amino acid peptide derived from the active site of human telomerase reverse transcriptase (hTERT). Originally developed as a cancer immunotherapy vaccine, now investigated for anti-inflammatory and anti-aging properties.
Research describes Hexarelin as the most potent synthetic GHRP, notable for GH release and cardiovascular protective properties.
A mitochondrial-derived peptide research associates with neuroprotection and cytoprotective cellular signalling.
A synthetic IGF-1 analog with extended half-life, researched for muscle hyperplasia and cellular proliferation.
A selective growth hormone secretagogue (ghrelin receptor agonist) studied for pulsatile GH release without meaningful cortisol or prolactin elevation.
Research describes kisspeptin as a master hypothalamic regulator that triggers the reproductive hormone cascade via GnRH.
Recombinant alpha-klotho longevity protein. Enhanced memory in aged primates.
A tripeptide derived from alpha-MSH, researched for anti-inflammatory effects in gut and intestinal tissue.
A GLP-1 receptor agonist research describes as effective for weight reduction and glycaemic control.
Livagen is a synthetic tetrapeptide composed of lysine, glutamic acid, aspartic acid, and alanine (Lys-Glu-Asp-Ala), developed by Professor Vladimir Khavinson as a bioregulator peptide targeting the liver. The liver is central to metabolic homeostasis, detoxification, protein synthesis, and bile production, and hepatocyte function declines progressively with age. Livagen is proposed to normalise hepatocyte gene expression by interacting with DNA to modulate chromatin condensation and transcriptional activity in aging liver tissue. One notable proposed mechanism is the promotion of chromatin decondensation in heterochromatin regions of aging hepatocytes, potentially reactivating silenced genes involved in liver regeneration and metabolic function.
A natural human antimicrobial peptide researched for broad-spectrum microbial defence and wound healing.
Macimorelin is an orally administered synthetic growth hormone secretagogue receptor (GHSR) agonist approved as a diagnostic agent for adult growth hormone deficiency (AGHD). Unlike other GH-stimulating peptides that require injection, macimorelin is taken as a single oral dose, making it a convenient and well-tolerated diagnostic tool. It stimulates the ghrelin receptor (GHS-R1a) to trigger a rapid release of growth hormone from the pituitary gland, and GH levels are measured at defined time points after ingestion. Macimorelin provides diagnostic accuracy comparable to the insulin tolerance test (ITT), the gold standard, but with significantly less patient risk and complexity.
GLP-1 agonist / GIP ANTAGONIST antibody-peptide conjugate. Monthly dosing. Novel mechanism.
Dual GLP-1/glucagon receptor agonist. Approved in China June 2025. Superior to semaglutide in Phase 3.
A synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH) that activates MC1R for photoprotection. EMA-approved (Scenesse) for erythropoietic protoporphyria (EPP). The most regulatory-advanced melanocortin peptide.
A synthetic hormone analogue researched for its ability to stimulate skin pigmentation via melanocortin receptors.
A splice variant of IGF-1 released by mechanical stress, researched for satellite cell activation and muscle repair.
An oral ghrelin mimetic that research shows reliably elevates GH and IGF-1 levels.
A mitochondria-encoded peptide research associates with AMPK activation, metabolic flexibility, and exercise capacity.
An acetylated Selank analogue researched for extended anxiolytic and nootropic activity via enhanced enzymatic stability.
An acetylated Semax analogue researched for enhanced BDNF upregulation and prolonged cognitive effects.
A coenzyme central to cellular energy and DNA repair that declines markedly with age.
A 36-amino acid neuropeptide associated with stress resilience and longevity. Higher NPY levels found in centenarians and Special Forces soldiers with superior stress performance.
A natural peptide hormone research associates with social bonding, trust, and stress reduction.
A synthetic BDNF mimetic tetrapeptide derived from Cerebrolysin that promotes neurogenesis without the side effects of full-length BDNF. Enhances dentate gyrus neurogenesis and improves spatial memory.
A signal peptide research describes as stimulating collagen I, III, and IV synthesis in skin fibroblasts.
A TREK-1 channel blocker researched for rapid antidepressant and pro-cognitive effects in animal models.
A PEGylated IGF-1 splice variant researched for systemic satellite cell activation and extended muscle repair signalling.
Peginesatide is a synthetic PEGylated peptide-based erythropoiesis-stimulating agent (ESA) that activates the erythropoietin (EPO) receptor to stimulate red blood cell production. Marketed briefly as Omontys, it was designed as an alternative to recombinant EPO products for treating anemia in chronic kidney disease. Unlike traditional ESAs, peginesatide is a synthetic dimeric peptide with no structural homology to erythropoietin, developed to avoid anti-EPO antibody-mediated pure red cell aplasia. It received FDA approval in March 2012 but was voluntarily withdrawn in February 2013 following reports of serious hypersensitivity reactions including fatal anaphylaxis. Research interest continues in modified formulations and the synthetic peptide EPO agonist concept remains scientifically valid.
Dual GLP-1/glucagon receptor agonist. MASH Phase 2 data in The Lancet.
A semi-synthetic polysaccharide researched for chondroprotective and anti-inflammatory effects in joint and bladder tissue.
Pinealon is a synthetic tripeptide composed of glutamic acid, aspartic acid, and arginine (Glu-Asp-Arg, or EDR). Developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, Pinealon is designed as a bioregulator peptide targeting the pineal gland. The pineal gland plays a central role in circadian rhythm regulation through melatonin synthesis. Pinealon is proposed to normalise pineal gland function by modulating gene expression related to melatonin production, potentially supporting sleep quality, circadian rhythm integrity, and neuroprotection. As a short peptide, it is theorised to penetrate cells and interact with DNA to restore age-related decline in pineal function. Evidence remains limited to preclinical studies.
A melanocortin receptor agonist researched for enhancing sexual desire via central nervous system pathways.
A first-in-class triple receptor agonist researched for its exceptional weight reduction and metabolic effects.
RGTA OTR4120 is a synthetic heparan sulfate mimetic designed to protect and stabilise endogenous growth factors within the extracellular matrix (ECM) at sites of tissue injury. Developed through research on glycosaminoglycan analogues, OTR4120 replaces damaged heparan sulfate proteoglycans destroyed during tissue injury by enzymatic degradation. By binding to heparan sulfate binding sites on matrix proteins and growth factors such as FGF, VEGF, TGF-beta, and HGF, OTR4120 shields these signalling molecules from proteolytic degradation, preserving their bioactivity and spatial organisation. This allows the natural wound healing cascade to proceed more efficiently, accelerating tissue regeneration in chronic wounds, burns, corneal injuries, and musculoskeletal damage.
A synthetic tuftsin-derived peptide researched for anxiety reduction and cognitive enhancement without sedation.
A long-acting GLP-1 receptor agonist. Extensively studied in clinical trials for glycemic control and body weight in T2D and obesity populations.
A synthetic nootropic peptide researched for cognitive enhancement, neuroprotection, and BDNF upregulation.
A shortened GHRH analogue that research shows stimulates the pituitary to release endogenous growth hormone.
Setmelanotide is a synthetic cyclic peptide that acts as a selective agonist of the melanocortin 4 receptor (MC4R). It was FDA-approved in 2020 under the brand name Imcivree for the treatment of chronic weight management in patients with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing. By restoring MC4R pathway signalling that is disrupted in these rare genetic obesity conditions, setmelanotide reduces hyperphagia and promotes clinically significant weight loss. It represents a precision medicine approach to obesity, targeting the specific molecular defect rather than broadly suppressing appetite. Clinical trials demonstrated sustained weight reduction in the indicated populations with an acceptable safety profile.
Research investigates this octapeptide's ability to modulate SNARE complex activity and reduce facial expression line depth.
A mitochondria-targeting peptide researched for reducing oxidative stress and improving cellular energy metabolism.
A GLP-1 and glucagon dual agonist researched for weight loss and liver fat reduction.
A synthetic fragment of Thymosin Beta-4 investigated for actin regulation, cell migration, and tissue repair pathways.
FDA-approved GHRH analog research shows significant visceral fat reduction, particularly in HIV-associated lipodystrophy.
A triple monoamine reuptake inhibitor researched for significant appetite suppression and weight reduction.
A thymus-derived peptide bioregulator researched for T-cell modulation and immune system restoration.
A synthetic pentapeptide representing the active site (amino acids 32-36) of thymopoietin. Promotes T-cell differentiation and immunomodulation without the instability of full-length thymopoietin.
A naturally occurring peptide research describes as a potent modulator of T-cell maturation and adaptive immunity.
Thymosin Beta-4 is known for its role in tissue repair and regeneration, making it valuable for recovery.
A zinc-dependent nonapeptide hormone produced by thymic epithelial cells that is essential for T-cell maturation and immune reconstitution. Thymulin levels decline dramatically with thymic involution during aging.
A dual GIP/GLP-1 receptor agonist that research associates with substantial body weight reduction and improved glycaemic control.
Vesugen is a synthetic tripeptide composed of lysine, glutamic acid, and aspartic acid (Lys-Glu-Asp), developed by Professor Vladimir Khavinson as a bioregulator peptide targeting the vascular system. It is designed to support endothelial function and microcirculation by modulating gene expression in vascular endothelial cells. Age-related vascular decline, characterised by endothelial dysfunction, reduced nitric oxide bioavailability, and impaired microcirculation, is a major contributor to cardiovascular disease and organ dysfunction. Vesugen is proposed to interact with DNA in endothelial cells to normalise transcription of genes involved in vascular homeostasis, including those regulating nitric oxide synthesis, angiogenesis, and endothelial integrity.
Vilon is a synthetic dipeptide consisting of lysine and glutamic acid (Lys-Glu), developed by Professor Vladimir Khavinson as a bioregulator peptide targeting the thymus gland. The thymus is the primary organ responsible for T-cell maturation and plays a critical role in adaptive immune function. With aging, the thymus undergoes involution, leading to progressive immunosenescence characterised by declining T-cell diversity and impaired immune surveillance. Vilon is proposed to modulate thymic gene expression, potentially restoring aspects of thymic function and supporting T-cell differentiation. As a dipeptide bioregulator, it represents the smallest functional unit in the Khavinson bioregulation framework, theorised to interact with DNA to normalise immune gene expression.
A 28-amino acid regulatory peptide researched for immune modulation, circadian rhythm, and neuroprotection.
Dual GLP-1/GIP receptor agonist with injectable and oral formulations.